Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Beta Bionics, Inc.
BBNX
NASDAQ·Healthcare·Medical - Equipment & Services·Mkt cap $744.2M
$16.76
▲ +0.36%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$8.80 - $32.71
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 18.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bionic pancreas technology with proven clinical efficacy and FDA approval
- Strategic partnerships with Xeris Pharmaceuticals and Abbott Diabetes Care enhancing product development and commercialization
- Innovative tubeless Patch Pump design addressing patient comfort and adherence challenges
- Expansion into type 2 diabetes market, capturing underserved patient population
Bear Case
2 risks
- Very high volatility (beta 3.4). Expect 3x market swings. Position size accordingly.
- Growth premium of 0.0x vs sector peers. Reasonable for this growth rate.
Growth
Moderate growth ahead
Increasing global prevalence of type 1 and type 2 diabetes requiring insulin therapy
Value
Growth premium of 0.0x vs sector peers. Reasonable for this growth rate.
Momentum
Hot
+68.2% over 3m
Quality
Strong
High-growth business (58% revenue growth, 57% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying BBNX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 4, 2026
APR 21, 2026
Reported EPS of -$0.49 vs -$0.53 consensus (+7.5% surprise). Revenue of $27.6M vs $26.9M expected (+2.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+7.5%
Next: Aug 4, 2026
Revenue trend · last 8Q
—
—
+145%
+36%
+54%
+63%
+57%
+57%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$15.0M
$16.7M
$20.4M
$17.6M
$23.2M
$27.3M
$32.1M
$27.6M
Margins · last 8Q
Gross
59.5%
Operating
-87.9%
Profit
-79.3%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
$17.00
▲ +1.4% vs $16.76
Latest: Goldman Sachs · $17.00 · May 27, 2026
1 analyst covering
vs Industry
How BBNX stacks vs Medical - Equipment & Services
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related